Metabolic launches Phase IIb trial
Thursday, 06 November, 2003
Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has commenced what it says is the largest clinical trial ever undertaken by an Australian biotech, a Phase IIb trial of its obesity drug, AOD9604.
The trial, with 300 "obese but otherwise health" participants, is being held at five sites in Adelaide, Melbourne, Sydney and Brisbane, the company said. It said it had amassed a large database of would-be trial participants after an item about the trial was screened on Channel Nine's A Current Affair program.
The three-month trial aims to evaluate the extent of weight loss achieved with the drug compared to a placebo. Participants will be subjected to daily oral dosing throughout the trial. Other parameters to be measured will include fat mass, blood cholesterol, glucose metabolism and perceived quality of life.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
